Shionogi & Co. has been awarded a $375 million project agreement by the Biomedical Advanced Research and Development Authority (BARDA) to develop S-892216, a long-acting injectabl ...

The substantial investment was funded by the part of HHS Administration for Strategic Preparedness and Response (ASPR) and ...

H.C. Wainwright & Co. reaffirmed its Buy rating and $15.00 price target for Emergent BioSolutions stock (NYSE:EBS). The ...

Moderna (MRNA) announced ongoing support from the U.S. Department of Health and Human Services, HHS, to accelerate the development of ...

The United States Biomedical Advanced Research and Development Authority (BARDA) has announced Vaxxas will receive US$2 million (AU$3.2 million) as a Concept Stage Winner in its multi-stage $50 ...

Shionogi will receive $375 million to develop a long-acting protease inhibitor designed to prevent SARS-CoV-2 infection in people who are immune compromised.

Moderna MRNA announced that the U.S. government, through the Biomedical Advanced Research and Development Authority (“BARDA”), has awarded the company $590 million to accelerate the ...

Learn more about a recompete NIH contract awarded to the Alliance for Advancing Biomedical Research to operate NCI's ...

While Moderna Inc. plans to cut its expenses by $1 billion in 2025, the company has received a little breathing room by a hefty U.S. Department of Health and Human Services (HHS) grant. The Biomedical ...